A cyclic hydroxylation dioxygenase mutant and its application in the degradation of polycyclic aromatic hydrocarbons.
By directing the evolution of terminal oxygenases of cyclic hydroxylated dioxygenases, MaRHD mutants were prepared, solving the problem of low catalytic efficiency of natural enzymes for high molecular weight polycyclic aromatic hydrocarbons (PAHs), and achieving efficient degradation of PAHs with a broad substrate spectrum.
Patent Information
- Application Number
- CN202611503236.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-24
- Publication Date
- 2026-11-17
AI Technical Summary
Existing natural cyclic hydroxylating dioxygenases have low catalytic efficiency and narrow substrate spectrum for high molecular weight polycyclic aromatic hydrocarbons, making it difficult to meet industrial remediation needs.
By directing the evolution of the terminal oxygenase of cyclic hydroxylated dioxygenases, MaRHD mutants were prepared, and their amino acid sequences were modified to improve the degradation efficiency and substrate applicability of high molecular weight polycyclic aromatic hydrocarbons.
The MaRHD mutant significantly improves the degradation efficiency of high molecular weight polycyclic aromatic hydrocarbons such as pyrene, and can completely convert them into pyrene-4,5-dihydrodiol within 12 hours, broadening the substrate spectrum and making it suitable for the efficient degradation of high molecular weight polycyclic aromatic hydrocarbons.
Smart Images

Figure CN123107941A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of bioengineering technology and relates to a cyclic hydroxylated dioxygenase mutant and its application in the degradation of polycyclic aromatic hydrocarbons.
[0002] Specifically, this application relates to semi-rationally designed and modified ring-hydroxylating dioxygenase (RHD) mutants (especially terminal oxygenases of RHD), their encoding genes, recombinant expression vectors, recombinant expression transformants, catalysts, and the application of ring-hydroxylating dioxygenase mutants in the degradation of polycyclic aromatic hydrocarbons (PAHs) and environmental bioremediation. Background Technology
[0003] Polycyclic aromatic hydrocarbons (PAHs) are a class of persistent organic pollutants containing two or more benzene rings. Those with two to three rings are called low molecular weight polycyclic aromatic hydrocarbons (LMW-PAHs), while those with four or more rings are called high molecular weight polycyclic aromatic hydrocarbons (HMW-PAHs). Due to their low water solubility, low volatility, and poor degradation, PAHs are highly stable in the environment and easily accumulate. Furthermore, their significant carcinogenic, mutagenic, and teratogenic effects have made the remediation of these pollutants a matter of great concern to the international community.
[0004] The high bond energies of aromatic structures in PAHs molecules make it difficult to break down the benzene ring. Currently, PAH degradation methods are mainly divided into three categories: first, chemical methods (such as supercritical water oxidation and photocatalytic oxidation), which typically involve harsh reaction conditions, high costs, and selectivity limitations on substrate structures; second, physical methods (such as gel precipitation, adsorption, extraction, and distillation), which often fail to completely remove pollutants due to the complex composition of soil in real-world environments, and subsequent treatment costs are high; and third, microbial methods, which utilize microorganisms to degrade PAHs using PAHs as the sole carbon source or through cometabolism. In comparison, using microorganisms and their metabolic enzyme systems to remediate PAH pollution is the most promising remediation technology currently available, aligning with green and sustainable development strategies, due to its mild, green, and non-reactive nature.
[0005] In the aerobic degradation of PAHs by microorganisms, ring-hydroxylating dioxygenase (RHD) is the key rate-limiting enzyme. RHD first catalyzes the dihydroxylation of the benzene ring in PAHs, disrupting the conjugated structure of the fused ring and forming a cis-dihydrodiol intermediate. Subsequently, this intermediate undergoes dehydrogenation and ring-opening reactions under the catalysis of other enzymes, causing the C-C bond to break and transforming into small molecule products that can be further metabolized. These small molecule products eventually enter the tricarboxylic acid cycle of microorganisms and are ultimately mineralized into CO2 and H2O after complete oxidation.
[0006] RHD is a multicomponent enzyme, typically composed of three parts: terminal oxygenase, ferredoxin (Fd), and ferredoxin reductase (FdR). The terminal oxygenase generally contains a large subunit (α) and a small subunit (β), forming an α3β3 heterohexamer structure; its α subunit contains a Rieske-type [2Fe-2S] cluster and non-heme mononuclear iron. Fd also carries a Rieske-type [2Fe-2S] cluster, while FdR consists of three functional modules: an FAD-binding domain, a NADH-binding domain, and a C-terminal domain.
[0007] The degradation difficulty of PAHs increases exponentially with the number of benzene rings. For low molecular weight polycyclic aromatic hydrocarbons (such as naphthalene and phenanthrene), some natural bacterial strains (such as Pseudomonas, Mycobacterium, and Nocardia) have shown effective degradation capabilities. In recent years, researchers have further isolated and identified several high-performance degrading bacteria. For example, in 2018, Shao Zongze et al. isolated a degrading bacterium from deep-sea sediments. Cycloclasticus sp. P1, through omics technology, clarified its degradation gene clusters and metabolic pathways. This strain achieved degradation rates of 98% and 92% for naphthalene and phenanthrene, respectively, within 5 days, significantly superior to most known strains (Appl. Environ. Microbiol., 2018, 84: e01261-18); Li Defeng et al. isolated it from a coking plant environment... Sphingobium sp. SJ10-10 exhibits the ability to simultaneously degrade phenanthrene and reduce hexavalent chromium [Cr(VI)], demonstrating significant application value in the remediation of complex pollution (J. Hazard. Mater., 2024, 475: 134889).
[0008] To address the challenge of degrading high-molecular-weight polycyclic aromatic hydrocarbons (PAHs), strategies such as rate-limiting enzyme molecular modification, strain adaptation, and rational reconstruction of degradation pathways have gradually become research hotspots. In 2025, Tang Hongzhi et al., with... Vibrio natriegensUsing Vmax as a chassis, the engineered strain VCOD-15 was constructed by improving metabolic conversion efficiency and integrating five highly efficient degradation gene clusters screened by INTIMATE technology. This strain exhibited excellent degradation activity against substrates such as biphenyl, naphthalene, and dibenzofuran within 48 h; however, it still could not degrade high molecular weight polycyclic aromatic hydrocarbons (Nature, 2025, 642: 1024-1033).
[0009] Current technologies still face significant challenges in degrading high molecular weight polycyclic aromatic hydrocarbons (such as pyrene and benzo[a]pyrene). The degradation of these hydrocarbons, discovered in 2003, remains a serious challenge. Mycobacterium vanbaalenii Although PYR-1 has been shown to catalyze the oxidation of benzo[a]pyrene, offering a potential avenue for the bioremediation of high molecular weight polycyclic aromatic hydrocarbons (PAHs), subsequent heterologous protein expression studies have revealed that its key enzyme, RHD, has a catalytic efficiency of only 17% for pyrene, far below the requirements for practical applications (Appl. Environ. Microbiol., 2004, 70: 340-345). Therefore, the low catalytic efficiency of natural RHD for high molecular weight PAHs remains a core rate-limiting step restricting the development of current microbial remediation technologies.
[0010] In summary, naturally sourced RHD has the following main drawbacks in practical applications: 1. Narrow substrate spectrum: It can usually only act on low molecular weight polycyclic aromatic hydrocarbons, and its catalytic efficiency on high molecular weight polycyclic aromatic hydrocarbons is extremely low.
[0011] 2. Insufficient catalytic efficiency: The activity of the natural enzymes reported so far is also difficult to meet the industrial remediation standards. Summary of the Invention
[0012] To address the issues of insufficient activity and narrow substrate spectrum of existing RHDs for high molecular weight polycyclic aromatic hydrocarbons, this invention provides a cyclic hydroxylation dioxygenase mutant and its application in the degradation of polycyclic aromatic hydrocarbons.
[0013] Specifically, this application provides a semi-rationally designed and modified ring-hydroxylating dioxygenase (RHD) mutant, its encoding gene, recombinant expression vector, recombinant expression transformant, catalyst, and the application of the ring-hydroxylating dioxygenase mutant in the degradation of polycyclic aromatic hydrocarbons (PAHs) and environmental bioremediation.
[0014] The cyclic hydroxylated dioxygenase mutant provided by this invention is an engineered RHD, especially the final mutant obtained by directed evolution of the terminal oxygenase in the RHD component. It significantly improves the degradation efficiency of high molecular weight polycyclic aromatic hydrocarbons (such as pyrene and benzo[a]pyrene) and further broadens the substrate spectrum compared with the wild type, thus having better application value in the degradation of PAHs.
[0015] The objective of this invention can be achieved through the following technical solutions: One of the technical solutions of the present invention: First, an RHD terminal oxygenase mutant is provided, which belongs to an isolated protein and is named... Ma RHD terminal oxygenase mutant is a protein with a new amino acid sequence formed by replacing one or more amino acid residues in the amino acid sequence shown in SEQ ID No. 2, such as Pro at position 31, Ala at position 136, Ile at position 231, Pro at position 236, Pro at position 246, Thr at position 273, Thr at position 361, Gly at position 365, Asp at position 378, and Met at position 397, with other amino acid residues.
[0016] Preferably, Ma The amino acid sequence of the RHD terminal oxygenase mutant is one of the following: (1) Replace isoleucine Ile at position 231 of the amino acid sequence shown in SEQ ID No. 2 with phenylalanine Phe, and replace proline Pro at position 246 of the amino acid sequence shown in SEQ ID No. 2 with isoleucine Ile; this is called M1; (2) Replace isoleucine Ile at position 231 of the amino acid sequence shown in SEQ ID No. 2 with phenylalanine Phe, replace proline Pro at position 246 of the amino acid sequence shown in SEQ ID No. 2 with isoleucine Ile, and replace methionine Met at position 397 of the amino acid sequence shown in SEQ ID No. 2 with leucine Leu; this is called M2; (3) Replace isoleucine Ile at position 231 of the amino acid sequence shown in SEQ ID No. 2 with phenylalanine Phe, replace proline Pro at position 246 of the amino acid sequence shown in SEQ ID No. 2 with isoleucine Ile, replace methionine Met at position 397 of the amino acid sequence shown in SEQ ID No. 2 with leucine Leu, replace threonine Thr at position 273 of the amino acid sequence shown in SEQ ID No. 2 with proline Pro, and replace proline Pro at position 236 of the amino acid sequence shown in SEQ ID No. 2 with serine Ser; this is called M3; (4) Replace isoleucine Ile at position 231 of the amino acid sequence shown in SEQ ID No. 2 with phenylalanine Phe, replace proline Pro at position 246 of the amino acid sequence shown in SEQ ID No. 2 with isoleucine Ile, replace methionine Met at position 397 of the amino acid sequence shown in SEQ ID No. 2 with leucine Leu, replace threonine Thr at position 273 of the amino acid sequence shown in SEQ ID No. 2 with proline Pro, replace proline Pro at position 236 of the amino acid sequence shown in SEQ ID No. 2 with serine Ser, replace threonine Thr at position 361 of the amino acid sequence shown in SEQ ID No. 2 with valine Val, and replace glycine Gly at position 365 of the amino acid sequence shown in SEQ ID No. 2 with alanine Ala; this is called M4; (5) Replace isoleucine Ile at position 231 of the amino acid sequence shown in SEQ ID No. 2 with phenylalanine Phe, replace proline Pro at position 246 of the amino acid sequence shown in SEQ ID No. 2 with isoleucine Ile, replace methionine Met at position 397 of the amino acid sequence shown in SEQ ID No. 2 with leucine Leu, replace threonine Thr at position 273 of the amino acid sequence shown in SEQ ID No. 2 with proline Pro, replace proline Pro at position 236 of the amino acid sequence shown in SEQ ID No. 2 with serine Ser, replace threonine Thr at position 361 of the amino acid sequence shown in SEQ ID No. 2 with valine Val, replace glycine Gly at position 365 of the amino acid sequence shown in SEQ ID No. 2 with alanine Ala, replace proline Pro at position 31 of the amino acid sequence shown in SEQ ID No. 2 with serine Ser, and replace... In the amino acid sequence shown in SEQ ID No. 2, alanine (Ala) at position 136 is replaced with serine (Ser), and aspartic acid (Asp) at position 378 is replaced with histidine (His); this is referred to as M5.
[0017] Among them, the protein having the amino acid sequence shown in SEQ ID No. 2 is... Ma RHD terminal oxygenase, encoding Ma The nucleic acid of RHD terminal oxygenase is called Ma The RHD terminal oxygenase nucleic acid has the nucleotide sequence shown in SEQ ID No. 1.
[0018] Since RHD consists of three parts: terminal oxygenase, ferredoxin (Fd), and ferredoxin reductase (FdR), this application also provides a cyclic hydroxylated dioxygenase mutant, abbreviated as... Ma RHD mutant, from Ma It consists of three parts: RHD terminal oxygenase mutant, ferredoxin (Fd), and ferredoxin reductase (FdR).
[0019] The cyclohydroxylated dioxygenase mutant ( Ma The RHD mutant significantly enhances activity against high molecular weight polycyclic aromatic hydrocarbons such as pyrene and also significantly improves substrate breadth.
[0020] in, Ma The amino acid sequence of ferredoxin (Fd) in the RHD mutant component is shown in SEQ ID No. 3, and the nucleotide sequence of its nucleic acid is shown in SEQ ID No. 4.
[0021] Ma The amino acid sequence of ferredoxin reductase (FdR) in the RHD mutant component is shown in SEQ ID No. 5, and the nucleotide sequence of its nucleic acid is shown in SEQ ID No. 6.
[0022] The second technical solution of the present invention: An isolated nucleic acid is provided, wherein the nucleic acid encodes as described in one of the technical solutions. Ma RHD terminal oxygenase mutant, the nucleic acid can also be called Ma RHD terminal oxygenase mutant nucleic acid or Ma RHD terminal oxygenase mutant gene.
[0023] The third technical solution of the present invention: Provides a system comprising the present invention Ma A recombinant expression vector for RHD-terminal oxygenase mutant nucleic acid. Preferably, the recombinant expression vector is a recombinant expression plasmid.
[0024] Since RHD is composed of three parts: terminal oxygenase, ferredoxin (Fd), and ferredoxin reductase (FdR), this application also provides a nucleic acid containing a cyclic hydroxylated dioxygenase mutant. Ma RHD mutant nucleic acid or MaA recombinant expression vector for the RHD mutant gene. The cyclic hydroxylated dioxygenase mutant nucleic acid includes... Ma RHD terminal oxygenase mutant nucleic acid, ferredoxin (Fd) nucleic acid, and ferredoxin reductase (FdR) nucleic acid.
[0025] Preferably, the recombinant expression vector of the present invention is the recombinant expression plasmid pRSFDuet-1- Ma RHD, the recombinant expression plasmid pRSFDuet-1- Ma RHD contains Ma RHD terminal oxygenase mutant nucleic acid, ferredoxin (Fd) nucleic acid, and ferredoxin reductase (FdR) nucleic acid.
[0026] The recombinant expression plasmid described above can be constructed using conventional methods in the art, and will encode the expression plasmid described in this invention. Ma The nucleic acid sequence of the RHD mutant gene is linked to various commercially available empty plasmids. The plasmid can be any plasmid conventional in the art, including but not limited to any one of the following expression vectors: pET expression vector, pRSF expression vector, pUC expression vector, or pBD expression vector. For different expression hosts, the preferred plasmid vector is different. Ma RHD mutant genes can be operatively cloned downstream of expression regulatory sequences in a selected vector to achieve the desired effect. Ma Constitutive or inducible expression of RHD mutants.
[0027] For the Escherichia coli host, the pRSFDuet-1 plasmid is preferred as a vector. The recombinant expression plasmid described in this invention can be prepared by the following method: by modifying the terminal oxygenase gene (… Ma The RHD terminal oxygenase mutant gene and the ferricoxin gene were amplified by PCR and then used for restriction endonuclease. Eco53k I and Hind III. The obtained DNA fragments containing terminal oxygenase and ferricoxin gene sequences were digested with two enzymes, and simultaneously digested with restriction endonucleases. Eco53k I and Hind III. The MCS-1 of the empty vector plasmid pRSFDuet-1 was digested with two enzymes. The digested terminal oxygenase, ferricodin gene DNA fragment, and empty vector plasmid were recovered using a nucleic acid gel. The digested terminal oxygenase, ferricodin gene DNA fragment, and empty vector plasmid pRSFDuet-1 were ligated using T4 DNA ligase. The same PCR method was then used to obtain… MaRHD's ferroreductase utilizes restriction endonucleases Nde I and Xho I. The obtained PCR fragment was digested with two enzymes, and simultaneously digested with restriction endonucleases. Nde I and Xho I. The empty vector plasmid pRSFDuet-1, which already contains the terminal oxygenase gene and the ferric reductase gene, was digested with two enzymes in MCS-2. The digested DNA fragment of the ferric reductase gene and the empty vector plasmid were recovered using a nucleic acid gel. The digested DNA fragment of the ferric reductase gene and the empty vector plasmid were then ligated using T4 DNA ligase to obtain the product containing the aforementioned genes. Ma The recombinant expression plasmid pRSFDuet-1-MaRHD for the RHD encoding gene is shown below. Figure 1 As shown.
[0028] The fourth technical solution of the present invention: A recombinant expression transformant comprising the recombinant expression vector described in this invention is provided.
[0029] The recombinant expression transformant of the present invention can be obtained by transforming the recombinant expression plasmid of the present invention into a host cell. The host cell is any conventional host cell in the art, including but not limited to any one of Escherichia coli, yeast, Bacillus, lactic acid bacteria, or filamentous fungi. The host cell of the present invention is preferably Escherichia coli, and more preferably... E. coli BL21(DE3). The recombinant expression plasmid described in this invention is transformed into host cells. E. coli In BL21(DE3), the recombinant expression transformant of the target can be obtained.
[0030] As an example, the recombinant expression plasmid pRSFDuet-1- described in this invention... Ma RHD transforms into E. coli E. coli In BL21(DE3), the recombinant expression transformant pRSDFuet-1-MaRHD / BL21(DE3) was obtained.
[0031] The fifth technical solution of the present invention: A recombinant Ma The preparation method of RHD catalyst, the recombinant Ma RHD catalysts are any of the following forms: (1) Cultivate the recombinant expression transformant of the present invention, and isolate the contents of the present invention. Ma Transformed cells of RHD, wherein the recombinant expression transformant contains the recombinant expression plasmid pRSFDuet-1- MaRHD, the recombinant expression plasmid pRSFDuet-1- Ma RHD contains Ma RHD terminal oxygenase mutant nucleic acid, ferredoxin (Fd) nucleic acid, and ferredoxin reductase (FdR) nucleic acid; (2) Frozen stem cells obtained by freeze-drying the transformed somatic cells as described in (1); (3) Crushed containing the above Ma Crude enzyme solution was prepared from transformed somatic cells of RHD and its mutants. (4) Containing the above Ma The pure enzyme solution was obtained by purifying the cell lysate of RHD and its mutants.
[0032] The conditions and methods for culturing the recombinant expression transformant are conventional in the art, and include the following steps: preparing the culture medium required for the growth of the recombinant expression transformant, culturing the recombinant expression transformant of the present invention, and obtaining... Ma RHD catalyst. The culture medium can be selected from conventional culture media in the art, including but not limited to TB, LB, or self-inducing media. For recombinant Escherichia coli, the preferred culture medium is TB medium: peptone 12 g / L, yeast extract 24 g / L, KH2PO4 2.31 g / L, K2HPO4 5 g / L, glycerol 5.2 g / L. The preferred culture method is as follows: the recombinant Escherichia coli constructed according to the above technical solution is inoculated into TB medium containing 50 μg / mL kanamycin and cultured at 37°C and 200 rpm for 12 h with shaking. Then, 1% (v / v) inoculation is added to a 2 L shake flask containing 500 mL of TB medium and cultured at 37°C and 200 rpm with shaking. 600 When the concentration reached 0.6, isopropyl-β-D-thiogalactoside (IPTG) was added to a final concentration of 0.2 mmol / L as an inducer. After induction at 16°C for 18 h, the cells were centrifuged and collected. The cells were then washed twice with phosphate-buffered saline (50 mM, pH 7.8) to obtain cells containing the aforementioned... Ma The resting cells of RHD were obtained and stored in a -20°C freezer for later use.
[0033] The sixth technical solution of the present invention: Provided by the present invention Ma RHD, Ma RHD mutants or recombinants Ma The application of RHD catalysts comprises the following steps: [The application is described in the original text]. Ma RHD, MaRHD mutants or recombinants Ma RHD catalyst was added to a phosphate buffer containing pyrene substrate to catalyze the oxidation of pyrene to pyrene-4,5-dihydrodiol.
[0034] in, Ma RHD includes Ma RHD terminal oxygenase, ferredoxin (Fd), and ferredoxin reductase (FdR) Ma The amino acid sequence of RHD terminal oxygenase is shown in SEQ ID No. 2, the amino acid sequence of ferredoxin (Fd) is shown in SEQ ID No. 3, and the amino acid sequence of ferredoxin reductase (FdR) is shown in SEQ ID No. 5.
[0035] Ma RHD mutants include Ma RHD terminal oxygenase mutant, ferredoxin (Fd), and ferredoxin reductase (FdR) Ma RHD terminal oxygenase mutants are as described in technical solution one.
[0036] Reorganization Ma The RHD catalyst was prepared using method five of the technical schemes.
[0037] The buffer solution can be selected from conventional buffer solutions in the art, including but not limited to phosphate, HEPES, or Tris-HCl, as long as the pH range is 7.0-8.0; the preferred buffer system is phosphate buffer with a pH of 7.8. The reaction temperature is 20-50℃, preferably 30℃.
[0038] The reaction process can be detected using conventional methods in the art, including but not limited to high performance liquid chromatography (HPLC), gas chromatography (GC), or thin-plate chromatography (TLC); the preferred detection method is high performance liquid chromatography (HPLC), which is used to analyze the conversion rate.
[0039] The specific analytical conditions for pyrene high-performance liquid chromatography are as follows: The chromatographic column was Elite C18, the mobile phase was methanol:water (0.1% trifluoroacetic acid) = 80:20 (v / v), the flow rate was 0.8 mL / min, the column temperature was 35℃, and the UV detection wavelength was 254 nm.
[0040] Compared with the prior art, the innovative improvement of this invention is as follows: The present invention provides Ma The RHD mutant exhibits significantly enhanced activity compared to the parent, completely converting pyrene into pyrene-4,5-dihydrodiol within 12 h. It also boasts a broader substrate spectrum, capable of converting PAHs with ring numbers ranging from 2 to 5, demonstrating promising application prospects in the efficient degradation of high molecular weight polycyclic aromatic hydrocarbons.
[0041] Therefore, the cyclic hydroxylated dioxygenase mutant provided by this invention has high catalytic activity and a broader substrate spectrum, and can effectively catalyze the oxidation reaction of high molecular weight polycyclic aromatic hydrocarbons such as pyrene, showing good application prospects in the fields of pollution control and bioremediation. Attached Figure Description
[0042] Figure 1 pRSFDuet-1- Ma RHD plasmid map.
[0043] Figure 2 Substrate profiles of natural cyclic hydroxylated dioxygenases and their mutant M5.
[0044] Figure 3 Cyclic hydroxylated dioxygenase Ma Distribution map of RHD modification sites. Detailed Implementation
[0045] The present invention will now be described in further detail with reference to specific embodiments. It is necessary to indicate here that the following specific embodiments are only used to describe the present invention more clearly and should not be construed as limiting the scope of protection of the present invention. Any non-essential improvements made to the present invention are included within the scope of protection of the present invention.
[0046] Unless otherwise stated, the specific experiments in the following examples were performed according to conventional methods and conditions in the art, or in accordance with the product instructions for the kit.
[0047] Example 1: Construction of a Cyclic Hydroxylated Dioxygenase Expression System RHD expression vector pRSFDuet-1- Ma The gene fragment encoding RHD was constructed by our laboratory. Ma RHD terminal oxygenase, Ma The ferricredoxin gene fragment of RHD and the MCS-1 of the empty vector pRSFDuet-1 were respectively processed by restriction endonucleases. Eco53k I and Hind III. After double enzyme digestion at 37℃ for 4 h, the digested target gene and vector were recovered from the gel using an agarose gel DNA recovery kit. Subsequently, the target gene and vector were ligated overnight at 16℃ using T4 DNA ligase, and the ligation solution was transformed into... E. coliBL21(DE3) was plated onto LB agar plates containing 50 μg / mL kanamycin and incubated at 37°C for 12 h. Sequencing verification was then performed (Beijing Qingke Biotechnology Co., Ltd.). After successful sequencing verification, the plasmid was extracted. The obtained plasmid was then compared with... Ma The ferric reductase gene fragment of RHD was used with restriction endonuclease. Nde I and Xho I was subjected to double enzyme digestion, and sequencing was performed to verify the results using the same method described above. After successful sequencing, the extracted plasmid was transformed. E. coli BL21(DE3) competent cells were used to obtain cells containing the recombinant plasmid pRSFDuet-1- Ma The recombinant expression strain of RHD, pRSFDuet-1- Ma RHD / BL21(DE3) was used to obtain a recombinant expression strain for subsequent applications. Ma Preparation of RHD catalyst.
[0048] In this embodiment, the recombinant plasmid pRSFDuet-1- Ma RHD contains Ma RHD terminal oxygenase nucleic acid, ferredoxin (Fd) nucleic acid, and ferredoxin reductase (FdR) nucleic acid, among which, Ma The nucleotide sequences of RHD terminal oxygenase nucleic acid are shown in SEQ ID No. 1, the nucleotide sequences of ferredoxin (Fd) nucleic acid are shown in SEQ ID No. 4, and the nucleotide sequences of ferredoxin reductase (FdR) nucleic acid are shown in SEQ ID No. 6.
[0049] Example 2 Ma Preparation of RHD terminal oxygenase mutant The cyclohydroxylating dioxygenase described in this embodiment Ma RHD originates from Martelella sp. AD-3. The aforementioned Ma The RHD catalytic system includes a terminal oxygenase component and ferredoxin (Fd) and ferredoxin reductase (FdR) that exchange electrons with it. This example only applies to... Ma The terminal oxygenase component in the RHD catalytic system was modified by site-directed mutagenesis, while Fd and FdR were not modified by amino acid sequence modification.
[0050] Specifically, using amino acids having the sequence shown in SEQ ID No. 2 MaRHD terminal oxygenase is a wild-type parent. One or more target amino acid sites of this terminal oxygenase are mutated at site-directed sites, including Pro at position 31, Ala at position 136, Ile at position 231, Pro at position 236, Pro at position 246, Thr at position 273, Thr at position 361, Gly at position 365, Asp at position 378, and Met at position 397.
[0051] Site-directed mutagenesis was performed according to the method described in the II Site-Directed Mutagenesis Kit (Stratagenem, Catalog No. 200502). Site-directed mutagenesis primers containing the corresponding mutant bases were designed based on the target amino acid site to be mutated, with wild-type primers included. Ma PCR amplification was performed using a recombinant plasmid encoding the RHD terminal oxygenase gene as a template. The nucleotide sequence of the codon corresponding to the target amino acid was altered, resulting in the substitution of the corresponding amino acid residue in the amino acid sequence shown in SEQ ID No. 2. Since the same amino acid can be encoded by different codons, the specific nucleotide form of the corresponding mutant codon is not particularly limited, as long as the targeted substitution of the target amino acid residue can be achieved.
[0052] It should be noted that the site-directed mutagenesis PCR in this embodiment targets... Ma The goal is to obtain genes encoding RHD terminal oxygenases, with the aim of obtaining genes encoding different... Ma The recombinant expression plasmid of the RHD terminal oxygenase mutant; the Fd encoding gene and the FdR encoding gene are not mutation targets in this embodiment, and their nucleotide sequences and encoded amino acid sequences remain unchanged.
[0053] The PCR reaction system is shown in Table 1.
[0054] Table 1. PCR reaction system The PCR reaction procedure is shown in Table 2.
[0055] Table 2. PCR reaction procedure After PCR amplification, the PCR product was treated with the restriction endonuclease Dpn I and digested at 37 °C for 2 h to digest the methylated wild-type parent plasmid used as the PCR template. The Dpn I-treated product was then transformed into competent *E. coli* cells and plated on LB agar containing 50 μg / mL kanamycin. The LB agar medium consisted of 10 g / L peptone, 5 g / L yeast extract, 10 g / L sodium chloride, and 20 g / L agar powder.
[0056] After culturing at 37 ℃ for 10–16 h, single clones were picked, and the resulting recombinant plasmids were sequenced for verification. The nucleotide sequences obtained from the sequencing were compared with those of the wild-type plasmid using SnapGene software. Ma The RHD terminal oxygenase encoding gene sequence was compared to confirm the nucleotide mutation at the target site and the resulting amino acid residue substitution.
[0057] After sequencing confirmed its correctness, the sample containing the corresponding... Ma Recombinant expression plasmids encoding the RHD terminal oxygenase mutant gene and corresponding engineered strains.
[0058] In the following Ma In the construction and catalytic performance evaluation of the RHD catalytic system, the above-obtained... Ma RHD terminal oxygenase mutants are used in combination with unmutated Fd and FdR to form a mixture containing mutant terminal oxygenase. Ma RHD catalytic system.
[0059] Example 3 Cyclic hydroxylated dioxygenase Ma Preparation of RHD and its mutant resting cells The monoclonal cells obtained in Example 2 were picked and transferred to test tubes containing 4 mL of LB medium (containing kanamycin) and cultured at 37°C and 200 rpm for 12-16 h with shaking. Then, they were inoculated at a rate of 1% (v / v) into shake flasks containing 100 mL of LB medium (containing kanamycin) and cultured at 37°C and 180 rpm with shaking. When the OD of the culture medium reached 0.6-0.8, isopropyl-β-D-thiogalactopyranoside (IPTG) was added to a final concentration of 0.2 mM to induce protein expression. After further culturing at 16°C for 18 h, the culture medium was centrifuged at 10,000 rpm to collect the cells. The cells were then washed twice with phosphate-buffered saline (50 mM, pH 7.8) to obtain the cells containing the aforementioned monoclonal cells. Ma The resting cells of RHD were obtained and stored in a -20°C freezer for later use.
[0060] Example 4 Chromatographic detection method for substrate pyrene and product pyrene-4,5-dihydrodiol I. HPLC Detection Method The enzyme-catalyzed reaction system was: 1 mM pyrene, OD = 5. MaRHD resting cells, 200 μL, 30℃, 24 h, enzymatic reaction was carried out in a shaking reactor (1000 rpm). During the reaction, 100 μL of the reaction solution was sampled intermittently, and 5 μL of 6 MHCl and 100 μL of acetonitrile solution were added to terminate the reaction. After mixing, the mixture was frozen at -20℃ for at least 0.5 h, followed by centrifugation at 1000 rpm for 3 min, and then filtered through an organic nylon membrane.
[0061] The specific analysis conditions are as follows: The chromatographic column was Elite C18, the mobile phase was methanol:water (0.1% trifluoroacetic acid) = 80:20 (v / v), the flow rate was 0.8 mL / min, the column temperature was 35℃, and the UV detection wavelength was 254 nm.
[0062] II. GC-MS Detection Method The enzyme-catalyzed reaction system was: 1 mM pyrene, OD = 5. Ma RHD resting cells, 200 μL, 30℃, 24 h, enzymatic reaction was carried out in a shaking reactor (1000 rpm). During the reaction, 100 μL of the reaction solution was sampled intermittently and an equal volume of ethyl acetate solution was added to the shaking reactor (1000 rpm) for extraction for 5 min. This operation was repeated 3 times. The resulting extract was concentrated to 100 μL by evaporation using a nitrogen blower. An equal volume of the derivatization reagent N,O-bis(trimethylsilyl)trifluoroacetamide was added, and the mixture was placed in a shaking reactor (1000 rpm) at 65℃ for 1 h. After derivatization, the mixture was filtered through an organic nylon membrane.
[0063] The specific analysis conditions are as follows: Gas chromatography-mass spectrometry (GC-MS) was performed using a Shimadzu GC-MS-QP2020NX mass spectrometer and a Shimadzu GC-2030 gas chromatograph. The Shimadzu gas chromatograph was equipped with a Shimadzu SH-Rtx-5MS capillary column (30m × 0.25mm × 0.25μm), and helium was used as the carrier gas. The GC-MS detection employed a programmed temperature ramp mode, with the following settings: initial column temperature set at 80℃; then ramped to 250℃ at a rate of 12℃ / min; further ramped to 300℃ at a rate of 15℃ / min, and held at this temperature for 30 min to ensure complete separation and elution of all target components in the sample, guaranteeing the accuracy and completeness of the detection results.
[0064] Example 5 Other chromatographic detection methods for PAHs For low molecular weight polycyclic aromatic hydrocarbons, the target compounds include naphthalene, acenaphthene, phenanthrene, fluorene, carbazole, anthracene, and dibenzofuran. The detection conditions were set as follows: an Elite C18 column was used; the mobile phase was methanol and an aqueous solution containing 0.1% trifluoroacetic acid, with a volume ratio of 70:30 (v / v); the mobile phase flow rate was controlled at 0.7 mL / min; the column temperature was maintained at 35℃; and a UV detector was used for detection at a wavelength of 254 nm.
[0065] For high molecular weight polycyclic aromatic hydrocarbons, the target compounds included pyrene, fluoranthene, benzo[a]anthracene, and benzo[a]pyrene. The detection conditions were set as follows: an Elite C18 column was used; the mobile phase was methanol and an aqueous solution containing 0.1% trifluoroacetic acid at a volume ratio of 80:20 (v / v); the mobile phase flow rate was controlled at 0.8 mL / min; the column temperature was maintained at 35℃; and a UV detector was used for detection at a wavelength of 254 nm.
[0066] Example 6 Ma Determination of the substrate pyrene by RHD and its mutants In a 1 mL reaction flask, 50 mM phosphate buffer (pH 7.8) was added, along with 200 µL of the resting cells prepared to OD = 5 as described in Example 3. 4 μL of 50 mM pyrene was added, and the reaction was carried out at 30°C and 200 rpm for 12 h. After the reaction, 5 μL of 6 M HCl and 200 μL of acetonitrile solution were added to terminate the reaction. The mixture was then centrifuged at 1000 rpm for 3 min and filtered through an organic nylon membrane. The pyrene conversion rate was analyzed using high-performance liquid chromatography (HPLC). The analytical method was as described in Example 4. The results show that the mutant of the present invention exhibits significant advantages in the catalytic degradation of pyrene to pyrene-4,5-dihydrodiol. The optimal mutant achieved a degradation rate of 90% for pyrene (Table 3). "+" indicates that the enzyme mutant achieved a degradation rate of 5%-20% for pyrene; "+++" indicates that the enzyme mutant achieved a degradation rate of 60%-70% for pyrene; and "+++++" indicates that the enzyme mutant achieved a degradation rate of 90%-99% for pyrene.
[0067] Table 3. Ma Degradation rate of pyrene by RHD and its different mutants in, Ma RHD includes Ma RHD terminal oxygenase, ferredoxin (Fd), and ferredoxin reductase (FdR) MaThe amino acid sequence of RHD terminal oxygenase is shown in SEQ ID No. 2, the amino acid sequence of ferredoxin (Fd) is shown in SEQ ID No. 3, and the amino acid sequence of ferredoxin reductase (FdR) is shown in SEQ ID No. 5.
[0068] Ma RHD mutants include Ma RHD terminal oxygenase mutant, ferredoxin (Fd), and ferredoxin reductase (FdR) Ma The RHD terminal oxygenase mutants are shown in the table above.
[0069] Example 7: Determination of the degradation rate of various PAHs by the optimal MaRHD mutant M5 The PAH degradation reaction in this experiment was carried out in a 1 mL reaction flask. The specific operation was as follows: 200 μL of resting cell solution (the resting cells were prepared according to Example 3, using 50 mM phosphate buffer at pH 7.8, and adjusted to OD = 5) was added to the reaction flask, followed by 4 μL of 50 mM different types of PAH substrates. The flask was then incubated at 30℃ and 200 rpm for 12 h with constant temperature shaking. After the reaction was completed, 5 μL of 6 M HCl solution and 200 μL of acetonitrile solution were added sequentially to terminate the reaction. The reaction system was then centrifuged at 1000 rpm for 3 min. After centrifugation, the supernatant was filtered through an organic nylon membrane for later use.
[0070] A positive control group and a negative control group were set up, and the procedures and treatments for each group are as follows: 1. Positive control group: Add 200 μL of 50 mM phosphate buffer (pH 7.8) to the reaction flask, then add 4 μL of 50 mM different types of PAH substrates, and incubate at 30℃ and 200 rpm for 12 h with constant temperature shaking. After the reaction, follow the termination, centrifugation and filtration procedures of the above experimental group for later use.
[0071] 2. Negative control group: Add 200 μL of resting cell solution (the resting cells are E. coli that do not contain the target gene) to the reaction flask. E. coliBL21(DE3) was prepared using 50 mM phosphate buffer at pH 7.8 (with its OD value adjusted to 5), and then 4 μL of different types of PAHs substrates at 50 mM were added. The mixture was then placed at 30°C and 200 rpm for 12 h under constant temperature shaking. After the reaction was completed, the mixture was processed according to the termination, centrifugation, and filtration procedures of the above experimental group and kept for later use.
[0072] All treated samples from the experimental group, positive control group, and negative control group were analyzed by high-performance liquid chromatography (HPLC), using the method described in Example 5. The peak area obtained from the positive control group was denoted as S2, the peak area obtained from the negative control group as S1, and the peak area obtained from the experimental group as S0. The PAHs degradation rate was calculated using the following formula: The results showed that the mutants of this invention exhibited significant advantages in the degradation reactions of different types of PAHs, demonstrating significant degradation effects on PAHs with different ring numbers and a significantly broadened substrate spectrum. The optimal mutant achieved a degradation rate of 99% for PAHs such as naphthalene, phenanthrene, and anthracene. Figure 2 As shown, benzo[a]pyrene was also degraded.
[0073] The above description of the embodiments is provided to enable those skilled in the art to understand and use the invention. It will be apparent to those skilled in the art that various modifications can be easily made to these embodiments, and the general principles described herein can be applied to other embodiments without inventive effort. Therefore, the present invention is not limited to the above embodiments, and any improvements and modifications made by those skilled in the art based on the description, without departing from the scope of the present invention, should be considered to still be within the protection scope of the present invention.
[0074] The sequence information involved in this invention is as follows: Proteins having the amino acid sequence shown in SEQ ID No. 2 are named Ma RHD terminal oxygenase, encoding Ma The nucleotide sequence of the nucleic acid encoding the RHD terminal oxygenase is shown in SEQ ID No. 1; the amino acid sequence encoding the ferredoxin in the RHD component is shown in SEQ ID No. 3, and the nucleotide sequence of its nucleic acid is shown in SEQ ID No. 4; the amino acid sequence encoding the ferredoxin reductase in the RHD component is shown in SEQ ID No. 5, and the nucleotide sequence of its nucleic acid is shown in SEQ ID No. 6.
[0075] SEQ ID No. 1( Ma RHD terminal oxygenase nucleic acid sequence: SEQ ID No. 2( Ma (RHD terminal oxygenase amino acid sequence): MNVRTIAGAA GAYSDAEILA MVDEKGGKYD PKIYVDEALY RLELERIFAR TWICMGHESQ 60 IPKPGDFTTA YIGEDPVVVV RQKDASIRVF LNQCQHRGMR ICRADSGNAK SFTCTYHGWA 120 YNQGGDLVSV PMEKEAFGGC LNKAEWGPKQ ARVETYKGLI FANWDADAPP LDEYLGDVKF 180 YMDIMLDRCE EGTEAIPGIQ KWVIPCNWKF AAEQFASDAY HAGTTSHLSG IMAGVPEDVD 240 ITQVAPPTEG LNVHLENGHG CGLFLRNPMF YMTILGPKVT EYLTTGPAYE ETVRRLGQGR 300 ADVHLCHTNV FPNLSFLAGINTVRMWQPRG PNEIEVWTFT VVDKTAPQEI KDEWRRNTSR 360 TFSAGGVFEQ DDGENWCDIQ QVLRGHVAQN QKFNIEMGTH TVTADNPEGF PGLSFAYTYS 420 EESARGLYRY WTEIMTAPDW PAIRRSQQRP LAAE 454 SEQ ID No. 3 (Feroxanone amino acid sequence): MAWMKVFPSA DVSEGEMKVF EGGPEPILVC RVDGEIHAVQ DTCTHDTWSL ADGFIEDGVI 60 ECSLHFAKFC VRTGKVKALP ACIALKVFPA KVDGDFIYIN C 101 SEQ ID No. 4 (Feroxin nucleic acid sequence): Atggcgtggatgaaggtgttcccttcggcagatgtgtcggagggagagatgaaggtattcgaaggtggccctgagccgatactggtgtgccgagtggacggcgaaatacacgccgtccaagacacctgtacgcatgacacatggtcactcgcggacggttttatcgaggacggagttatcgagtgcagtctgcacttcgcgaaattttgcgtcagaaccggcaaggtgaaggccctgcctgcttgtgaggcactcaaggtgtttcctgcaaaggtcgacggcgacttcatatacattaactgctga SEQ ID No. 5 (ferredoxin reductase amino acid sequence): MERIIIIGGG LAAVTAAKTL RTEGFEGAVT ILSEERHLPY DRPPLSKAVL QGAADAQSTC 60 LLKAEVAQNL AIDLQINQRA EAIDRDAQVV RLSSSQRLPY DRLLIATGSR ARTLDGPFEG 120 KGNVFYLRTI DDAECLRAQM VPGKRLLSIG AGWIGLEVAA TARKSGMEAV VVELADRLCG 180 RSLPPDVGVA LADVHRSNGT VIHLNTSIVT VGGEDQVESV TLSNGEMLAV DVVVIGIGAI 240 ANDAIAREAG LETGNGVIVD EFLRTSDPLI YAAGDVAAMR VGDGQPTRME SWANAQDQAA 300 AAARNMLGKK EPYAINTWFW SDQYDLNIQM IGDNQPEGGT ILVRKGEGRS FTRFAVIGDV 360 LVGAICFGAP RDMAIVRRLI SKGYAVTDDS LITATDLRKL L 401 SEQ ID No. 6 (ferredoxin reductase nucleic acid sequence):
Claims
1. An RHD terminal oxygenase mutant, characterized in that: for Ma RHD terminal oxygenase mutant, with an amino acid sequence of one of the following: (1) Replace isoleucine Ile at position 231 in the amino acid sequence shown in SEQ ID No. 2 with phenylalanine Phe, and replace proline Pro at position 246 in the amino acid sequence shown in SEQ ID No. 2 with isoleucine Ile; (2) Replace isoleucine Ile at position 231 of the amino acid sequence shown in SEQ ID No. 2 with phenylalanine Phe, replace proline Pro at position 246 of the amino acid sequence shown in SEQ ID No. 2 with isoleucine Ile, and replace methionine Met at position 397 of the amino acid sequence shown in SEQ ID No. 2 with leucine Leu; (3) Replace isoleucine Ile at position 231 of the amino acid sequence shown in SEQ ID No. 2 with phenylalanine Phe, replace proline Pro at position 246 of the amino acid sequence shown in SEQ ID No. 2 with isoleucine Ile, replace methionine Met at position 397 of the amino acid sequence shown in SEQ ID No. 2 with leucine Leu, replace threonine Thr at position 273 of the amino acid sequence shown in SEQ ID No. 2 with proline Pro, and replace proline Pro at position 236 of the amino acid sequence shown in SEQ ID No. 2 with serine Ser; (4) Replace isoleucine Ile at position 231 of the amino acid sequence shown in SEQ ID No. 2 with phenylalanine Phe, replace proline Pro at position 246 of the amino acid sequence shown in SEQ ID No. 2 with isoleucine Ile, replace methionine Met at position 397 of the amino acid sequence shown in SEQ ID No. 2 with leucine Leu, replace threonine Thr at position 273 of the amino acid sequence shown in SEQ ID No. 2 with proline Pro, replace proline Pro at position 236 of the amino acid sequence shown in SEQ ID No. 2 with serine Ser, replace threonine Thr at position 361 of the amino acid sequence shown in SEQ ID No. 2 with valine Val, and replace glycine Gly at position 365 of the amino acid sequence shown in SEQ ID No. 2 with alanine Ala; (5) Replace isoleucine Ile at position 231 of the amino acid sequence shown in SEQ ID No. 2 with phenylalanine Phe, replace proline Pro at position 246 of the amino acid sequence shown in SEQ ID No. 2 with isoleucine Ile, replace methionine Met at position 397 of the amino acid sequence shown in SEQ ID No. 2 with leucine Leu, replace threonine Thr at position 273 of the amino acid sequence shown in SEQ ID No. 2 with proline Pro, replace proline Pro at position 236 of the amino acid sequence shown in SEQ ID No. 2 with serine Ser, replace threonine Thr at position 361 of the amino acid sequence shown in SEQ ID No. 2 with valine Val, replace glycine Gly at position 365 of the amino acid sequence shown in SEQ ID No. 2 with alanine Ala, replace proline Pro at position 31 of the amino acid sequence shown in SEQ ID No. 2 with serine Ser, and replace... In the amino acid sequence shown in SEQ ID No. 2, alanine (Ala) at position 136 is replaced with serine (Ser), and aspartic acid (Asp) at position 378 is replaced with histidine (His).
2. A cyclic hydroxylated dioxygenase mutant, characterized in that: for Ma RHD mutant, from Ma It consists of three parts: RHD terminal oxygenase mutant, ferric reductin, and ferric reductase. Among them, the Ma The RHD terminal oxygenase mutant is as described in claim 1; The amino acid sequence of ferricyanide is shown in SEQ ID No. 3; The amino acid sequence of ferroreductase is shown in SEQ ID No.
5.
3. An isolated nucleic acid, characterized in that, The nucleic acid encodes the RHD terminal oxygenase mutant as described in claim 1 or the cyclic hydroxylated dioxygenase mutant as described in claim 2.
4. The recombinant expression vector according to claim 3, characterized in that, The nucleotide sequence of ferricyanide nucleic acid is shown in SEQ ID No. 4; The nucleotide sequence of ferroreductase nucleic acid is shown in SEQ ID No.
6.
5. A recombinant expression vector, characterized in that, The recombinant expression vector comprises the nucleic acid as described in claim 3.
6. A recombinant expression transformant, characterized in that, It includes the recombinant expression vector as described in claim 5.
7. A recombinant cyclic hydroxylated dioxygenase mutant catalyst, characterized in that, The recombinant dioxygenase mutant catalyst is any one of the following forms: (1) Cultivate the recombinant expression transformant according to claim 5, and isolate the transformant cells or resting cells containing the cyclic hydroxylated dioxygenase mutant; (2) The transformed somatic cells as described in (1) are broken up to separate the crude enzyme solution containing the cyclic hydroxylated dioxygenase mutant; (3) The cyclic hydroxylated dioxygenase mutant obtained by purifying the crude enzyme solution as described in (2).
8. The application of the cyclohydroxylated dioxygenase mutant as described in claim 2, or the recombinant cyclohydroxylated dioxygenase mutant catalyst as described in claim 7, in the degradation of polycyclic aromatic hydrocarbons.
9. The application according to claim 8, characterized in that, The polycyclic aromatic hydrocarbon substrates are naphthalene, acenaphthene, phenanthrene, fluorene, carbazole, anthracene, dibenzofuran, pyrene, fluoranthene, benzo[a]anthracene, and benzo[a]pyrene.
10. The application according to claim 8, characterized in that, The degradation products of polycyclic aromatic hydrocarbons include naphthalene dihydrodiol, acenaphthene dihydrodiol, phenanthrene dihydrodiol, fluorene dihydrodiol, carbazole dihydrodiol, anthracene dihydrodiol, dibenzofuran dihydrodiol, pyrene dihydrodiol, fluoranthene dihydrodiol, benzo[a]anthracene dihydrodiol, and benzo[a]pyrene dihydrodiol.
